ClinicalTrials.gg
CompletedNCT07856771Updated Oct 5, 2026

Conventional Curettage Versus Endoscopic Microdebrider-Assisted Adenoidectomy in Children

An interventional study of Conventional Curretage Adenoidectomy and Endoscopic Microdebrider-Assisted Adenoidectomy in Adenoid Hypertrophy, sponsored by Allama Iqbal Teaching Hospital. Completed at 1 site in Pakistan. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Allama Iqbal Teaching Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2025, registered Sep 2026).
Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
3 Years to 16 Years
Sex
All
01

Study summary

The purpose of this randomized clinical trial is to compare two surgical methods for removing enlarged adenoids in children: conventional curettage adenoidectomy and endoscopic microdebrider-assisted adenoidectomy. Enlarged adenoids can cause problems such as snoring, mouth breathing, obstructive sleep apnea, and changes in facial appearance.

The main question this study aims to answer is:

  • Does endoscopic microdebrider-assisted adenoidectomy result in different operative outcomes compared with conventional curettage adenoidectomy?

The study will include 88 children aged 3-16 years who have enlarged adenoids and symptoms such as obstructive sleep apnea, mouth breathing, or snoring. Participants will be randomly assigned to one of two groups:

  • Group A: Adenoidectomy using a conventional adenoid curette.
  • Group B: Adenoidectomy using a microdebrider while viewing the adenoids with an endoscope.

All procedures will be performed under general anesthesia. The researchers will record the duration of the operation and the amount of blood lost during surgery. These outcomes will be compared between the two groups to determine whether the surgical techniques differ in operative time and blood loss.

Parents or guardians will provide informed consent before their child participates in the study.

02

Conditions studied

  • Adenoid Hypertrophy

Keywords

  • Adenoidectomy
  • Adenoid Hypertrophy
  • Endoscopic Adenoidectomy
  • Microdebrider
  • Curettage Adenoidectomy
  • Pediatric Adenoidectomy
  • Obstructive Sleep Apnea
  • Snoring
  • Mouth Breathing
  • Operative time
  • Blood loss
03

In context

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

This study's enrollment of 88 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Allama Iqbal Teaching Hospital is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Signs and symptoms of enlarged adenoid i.e.,

  • History of obstructive sleep apnea
  • Mouth breathing
  • Snoring
  • Adenoid facies

Exclusion Criteria:

  • Craniofacial syndromes (cleft lip, cleft palate)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
88 participants (actual)

Study arms

  • Active comparator
    Conventional Curretage Adenoidectomy

    Participants will undergo conventional adenoidectomy using a St. Clair Thompson adenoid curette under general anesthesia with orotracheal intubation.

    Procedure: Conventional Curretage Adenoidectomy

  • Experimental
    Endoscopic Microdebrider-Assisted Adenoidectomy

    Participants will undergo adenoidectomy using a microdebrider under endoscopic visualization.

    Procedure: Endoscopic Microdebrider-Assisted Adenoidectomy

Interventions

  • ProcedureConventional Curretage Adenoidectomy

    Surgical removal of enlarged adenoid tissue using a St. Clair Thompson adenoid curette under general anesthesia with orotracheal intubation.

  • ProcedureEndoscopic Microdebrider-Assisted Adenoidectomy

    A 45° angled blade will be introduced through the oropharynx, with irrigation at 15 mL/min and the microdebrider set at 5000 oscillations/second. A zero-degree endoscope will be inserted through either nostril for visualization during the procedure.

06

What researchers measure

Primary outcomes

  1. Intraoperative Blood Loss

    Total blood loss during adenoidectomy, measured from the graduated suction cylinder and by weighing pre-weighed roller packs used in the nasopharynx, with 1 gram of blood equivalent to 1 mL.

    Time frame: From the start of surgery until completion of adenoidectomy and handover of the patient to the anesthetist for extubation.

Other outcomes

  1. Operative time

    Total duration of surgery in minutes, measured from the start of surgical incision to completion of wound closure.

    Time frame: From the start of surgical incision until completion of wound closure

07

Study locations

1 site
  • Allama Iqbal Teaching Hospital
    Dera Ghazi Khan, Punjab Province 32200, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Oct 2025, 5 months.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 5 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 5, 2026
StartActual
May 1, 2025
Primary completionActual
Oct 30, 2025
CompletionActual
Oct 30, 2025
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856771
Lead sponsor
Allama Iqbal Teaching Hospital
Responsible party
Hasham Wahid (Principal Investigator, Allama Iqbal Teaching Hospital) — Principal investigator
First posted
Oct 5, 2026
Start date
May 1, 2025
Primary completion
Oct 30, 2025
Completion
Oct 30, 2025
Last update
Oct 5, 2026

Study contacts

Muhammad W Saleem, FCPS
study chair · Allama Iqbal Teaching Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion